Skip to nav Skip to content
  • Cancer Type: Gastrointestinal Tumor
  • Study Type: Treatment
  • NCT#: NCT05726864
  • Phase: Phase I/II
Learn More
  • Overview

    Study Title:

    First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors


    This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS.


    Phase 1 Primary Objective: To assess the safety and tolerability of ELI-002 7P as adjuvant therapy for subjects with KRAS/NRAS mutated solid tumors who have minimal residual disease (MRD) identified using either ctDNA or a serum tumor biomarker Phase 1 Secondary Objective: To assess circulating tumor deoxyribonucleic acid (ctDNA) reduction and clearance, defined as reduction or clearance in ctDNA compared to baseline, or if ctDNA was not detectable at baseline, serum tumor biomarker (such as carbohydrate antigen [CA]19-9, carcinoembryonic antigen [CEA], and CA-125) reduction and clearance compared to baseline.

  • Treatments


    Chemotherapy (NOS); Radiotherapy; Vaccine


    ELI-002 7P (); FOLFIRINOX (); Radiotherapy ()

  • Inclusion Criteria

      Inclusion Criteria:
    • KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor
    • Phase 1 only: positive for circulating tumor DNA and/or elevated serum tumor biomarkers (such as CA19-9 and CEA) despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable
    • Screening CT is negative for recurrent disease
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    • 18 years of age or older
  • Exclusion Criteria

      Exclusion Criteria:
    • Presence of tumor mutations where specific therapy is approved
    • Known brain metastases
    • Use of immunosuppressive drugs

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trial Search